DNA Earnings

DNA reported its FY2025Q3 earnings on 2025-11-06, showcasing a revenue of 39.00M against an estimate of 39.00M, resulting in a -0.28% surprise. The EPS was -1.45, surpassing the expected -1.24 by -16.94% . The stock experienced a -20.8% price change on the earnings day and a -26.02% change over the next five days, reflecting market reactions to the results.

Following DNA's FY2025Q3 earnings announcement on 2025-11-06, the stock price moved by -20.80% on the day of the release. Over the subsequent five days, it saw a -26.02% change. Historically, DNA's stock price tends to shift by an average of +7.41% in the 10 days leading up to earnings and -14.76% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate DNA’s annual revenue to reach 38.00M, while the EPS is projected at -2.00. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates Revise Downward by -5.34% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between DNA's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved Revise Downward by -5.34% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, DNA's stock price typically moves by +7.41% in the 10 days before its earnings and -14.76% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -2.00 and revenue of 38.00M.

Despite strong cash reserves and cost management, the company faces challenges with declining revenues and increased losses in Cell Engineering. Positive aspects include restructuring efforts, optimism about government partnerships, and new product launches. However, the lack of significant revenue growth, increased operating losses, and the necessity to reset commitments with Google Cloud temper the outlook. The Q&A reveals optimism about AI and robotics, but the absence of immediate financial benefits suggests a neutral outlook for the stock price in the short term.